Chemical Science,
Journal Year:
2023,
Volume and Issue:
14(11), P. 2901 - 2909
Published: Jan. 1, 2023
Although
metallacycle-based
photosensitizers
have
attracted
increasing
attention
in
biomedicine,
their
clinical
application
has
been
hindered
by
inherent
dark
toxicity
and
unsatisfactory
phototherapeutic
efficiency.
Herein,
we
employ
a
π-expansion
strategy
for
ruthenium
acceptors
to
develop
series
of
Ru(ii)
metallacycles
(Ru1-Ru4),
while
simultaneously
reducing
enhancing
phototoxicity,
thus
obtaining
high
phototoxicity
index
(PI).
These
enable
deep-tissue
(∼7
mm)
fluorescence
imaging
reactive
oxygen
species
(ROS)
production
exhibit
remarkable
anti-tumor
activity
even
under
hypoxic
conditions.
Notably,
Ru4
the
lowest
toxicity,
highest
ROS
generation
ability
an
optimal
PI
(∼146).
Theoretical
calculations
verify
that
exhibits
largest
steric
bulk
singlet-triplet
energy
gap
(ΔEST,
0.62
eV).
In
vivo
studies
confirm
allows
effective
safe
phototherapy
against
A549
tumors.
This
work
is
expected
open
new
avenue
design
high-performance
metal-based
potential
applications.
Angewandte Chemie International Edition,
Journal Year:
2023,
Volume and Issue:
62(24)
Published: March 9, 2023
Conventional
photocages
only
respond
to
short
wavelength
light,
which
is
a
significant
obstacle
developing
efficient
phototherapy
in
vivo.
The
development
of
activated
by
near-infrared
(NIR)
light
at
wavelengths
from
700
950
nm
important
for
vivo
studies
but
remains
challenging.
Herein,
we
describe
the
synthesis
photocage
based
on
ruthenium
(Ru)
complex
with
NIR
light-triggered
photocleavage
reaction.
commercial
anticancer
drug,
tetrahydrocurcumin
(THC),
was
coordinated
RuII
center
create
Ru-based
that
readily
responsive
760
nm.
inherited
properties
THC.
As
proof-of-concept,
further
engineered
self-assembled
photocage-based
nanoparticle
system
amphiphilic
block
copolymers.
Upon
exposure
nm,
Ru
complex-based
were
released
polymeric
nanoparticles
and
efficiently
inhibited
tumor
proliferation
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(5), P. 4591 - 4600
Published: March 1, 2023
Fluorescence-guided
phototherapy,
including
photodynamic
and
photothermal
therapy,
is
considered
an
emerging
noninvasive
strategy
for
cancer
treatments.
Organic
molecules
are
promising
theranostic
agents
because
of
their
facile
construction,
simple
modification,
good
biocompatibility.
systems
that
integrated
multifunctionalities
in
a
single
component
achieved
high
efficiency
both
imaging
therapies
rarely
reported
as
the
inherently
competitive
energy
relaxation
pathways
hard
to
modulate,
fluorescence
quenching
occurs
upon
molecular
aggregation.
Herein,
versatile
platform
with
near-infrared
emission,
quantum
yield,
robust
reactive
oxygen
species
production,
excellent
conversion
was
developed
based
on
aggregation-induced
emission
luminogen,
namely,
TPA-TBT.
In
vivo
studies
revealed
TPA-TBT
nanoaggregates
exhibit
outstanding
therapy
efficacy
ablate
tumors
inoculated
mouse
model.
This
work
offers
design
develop
one-for-all
by
modulating
utilizing
excitons
full.
Advanced Functional Materials,
Journal Year:
2023,
Volume and Issue:
33(25)
Published: March 10, 2023
Abstract
As
a
less
O
2
‐dependent
photodynamic
therapy
(PDT),
type
I
PDT
is
an
effective
approach
to
overcome
the
hypoxia‐induced
low
efficiency
against
solid
tumors.
However,
commonly
used
metal‐involved
agents
suffer
from
long‐term
biosafety
concern.
Herein,
metal‐free
photosensitizer,
N
‐doped
carbon
dots/mesoporous
silica
nanoparticles
(NCDs/MSN,
≈40
nm)
nanohybrid
with
peroxidase
(POD)‐like
activity
for
synergistic
and
enzyme‐activity
treatment,
developed
on
gram
scale
via
facile
one‐pot
strategy
through
mixing
source
precursor
assistance
of
template.
Benefiting
narrow
bandgap
(1.92
eV)
good
charge
separation
capacity
NCDs/MSN,
upon
640
nm
light
irradiation,
excited
electrons
in
conduction
band
can
effectively
generate
•−
by
reduction
dissolved
one‐electron
transfer
process
even
under
hypoxic
conditions,
inducing
apoptosis
tumor
cells.
Moreover,
photoinduced
partially
transform
into
more
toxic
•
OH
two‐electron
reduction.
POD‐like
NCDs/MSN
catalyze
endogenous
H
microenvironment,
further
synergistically
ablating
4T1
Therefore,
mass
production
way
synthesize
novel
photosensitizer
enzyme‐mimic
treatment
tumors
provided,
which
exhibits
promising
clinical
translation
prospects.
Chemical Science,
Journal Year:
2023,
Volume and Issue:
14(11), P. 2901 - 2909
Published: Jan. 1, 2023
Although
metallacycle-based
photosensitizers
have
attracted
increasing
attention
in
biomedicine,
their
clinical
application
has
been
hindered
by
inherent
dark
toxicity
and
unsatisfactory
phototherapeutic
efficiency.
Herein,
we
employ
a
π-expansion
strategy
for
ruthenium
acceptors
to
develop
series
of
Ru(ii)
metallacycles
(Ru1-Ru4),
while
simultaneously
reducing
enhancing
phototoxicity,
thus
obtaining
high
phototoxicity
index
(PI).
These
enable
deep-tissue
(∼7
mm)
fluorescence
imaging
reactive
oxygen
species
(ROS)
production
exhibit
remarkable
anti-tumor
activity
even
under
hypoxic
conditions.
Notably,
Ru4
the
lowest
toxicity,
highest
ROS
generation
ability
an
optimal
PI
(∼146).
Theoretical
calculations
verify
that
exhibits
largest
steric
bulk
singlet-triplet
energy
gap
(ΔEST,
0.62
eV).
In
vivo
studies
confirm
allows
effective
safe
phototherapy
against
A549
tumors.
This
work
is
expected
open
new
avenue
design
high-performance
metal-based
potential
applications.
